Artificial Blood: Global Markets to 2028
Report Highlights
The global artificial blood market reached $23.9 million in 2022, should reach $26.1 million by 2023 and $40.5 million by 2028 with a compound annual growth rate (CAGR) of 9.2% during the forecast period of 2023-2028.
Report Includes
- 41 tables
- An overview of the global markets for artificial blood
- Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Highlights of the market potential and characterization of artificial blood market by product, application, and region
- Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
- Coverage of recent advances, emerging technologies, and developments of the industry
- Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
- Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma
Report Scope
The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2023-2028 |
| Base year market size | $23.9 million |
| Market size forecast | $40.5 million |
| Growth rate | CAGR of 9.2% for the forecast period of 2023-2028 |
| Units considered | $ Millions |
| Segments covered | Source, Type |
| Regions covered | North America, Europe, Emerging markets |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global market for potential artificial blood is estimated to grow from nearly $6.2 billion in 2022 to $15.6 billion by 2027 with a compound annual growth rate (CAGR) of 20.5% for the period of 2022-2027.
Report Includes
- 144 tables
- Country specific data and analysis for USA, Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, China, Japan, India, Australia, Brazil, and South Africa
- Identification of growth-driving factors influencing the artificial blood market, as well as opportunities, restraints, and technological developments
- Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.